MX347788B - Diagnosis y tratamiento de preeclampsia. - Google Patents

Diagnosis y tratamiento de preeclampsia.

Info

Publication number
MX347788B
MX347788B MX2013001577A MX2013001577A MX347788B MX 347788 B MX347788 B MX 347788B MX 2013001577 A MX2013001577 A MX 2013001577A MX 2013001577 A MX2013001577 A MX 2013001577A MX 347788 B MX347788 B MX 347788B
Authority
MX
Mexico
Prior art keywords
preeclampsia
diagnosis
relates
treatment
disease
Prior art date
Application number
MX2013001577A
Other languages
English (en)
Spanish (es)
Inventor
Hansson Stefan
Åkerström Bo
Original Assignee
A1M Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A1M Pharma Ab filed Critical A1M Pharma Ab
Publication of MX347788B publication Critical patent/MX347788B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/99—Miscellaneous (1.14.99)
    • C12Y114/99003—Heme oxygenase (1.14.99.3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
MX2013001577A 2007-02-12 2008-02-12 Diagnosis y tratamiento de preeclampsia. MX347788B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0700339 2007-02-12
PCT/EP2008/001051 WO2008098734A1 (en) 2007-02-12 2008-02-12 Diagnosis and treatment of preeclampsia

Publications (1)

Publication Number Publication Date
MX347788B true MX347788B (es) 2017-05-12

Family

ID=39295873

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013001577A MX347788B (es) 2007-02-12 2008-02-12 Diagnosis y tratamiento de preeclampsia.
MX2009008408A MX2009008408A (es) 2007-02-12 2008-02-12 Diagnosis y tratamiento de preeclampsia.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2009008408A MX2009008408A (es) 2007-02-12 2008-02-12 Diagnosis y tratamiento de preeclampsia.

Country Status (18)

Country Link
US (3) US8568999B2 (enExample)
EP (3) EP2613150A1 (enExample)
JP (2) JP5604111B2 (enExample)
KR (2) KR101454013B1 (enExample)
AU (1) AU2008214837B2 (enExample)
BR (1) BRPI0808340A2 (enExample)
CA (1) CA2674204C (enExample)
DK (2) DK2614832T3 (enExample)
EA (2) EA022609B1 (enExample)
ES (2) ES2426069T3 (enExample)
HR (2) HRP20130809T1 (enExample)
HU (1) HUE031613T2 (enExample)
MX (2) MX347788B (enExample)
NZ (1) NZ578077A (enExample)
PL (2) PL2111555T3 (enExample)
PT (2) PT2111555E (enExample)
WO (1) WO2008098734A1 (enExample)
ZA (1) ZA200905101B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2426069T3 (es) * 2007-02-12 2013-10-21 A1M Pharma Ab Diagnóstico de preeclampsia
EP2313106B1 (en) 2008-07-18 2016-03-30 A1M Pharma AB Medical use of the radical scavenger and antioxidant alpha-1-microglobulin
WO2011095981A1 (en) * 2010-02-03 2011-08-11 St. John's Research Institute An in-vitro method for characterizing hemoglobin variant
AU2011231982B2 (en) * 2010-03-24 2014-02-20 Preelumina Diagnostics Ab HbF and A1M as early stage markers for preeclampsia
KR101858765B1 (ko) * 2010-03-31 2018-05-16 세키스이 메디칼 가부시키가이샤 면역 크로마토그래피를 이용한 측정 방법, 면역 크로마토그래피용 테스트 스트립 및 면역 크로마토그래피용 측정 시약 키트
US20150004632A1 (en) 2011-10-14 2015-01-01 Aarhus Universitet Diagnostic and prognostic use of prombp-complexes
MX357656B (es) * 2012-09-05 2018-07-18 A1M Pharma Ab Alfa-1-microglobulina para usarse en tratamiento de enfermedades relacionadas a mitocondrias.
US20140186332A1 (en) * 2012-12-28 2014-07-03 NX Pharmagen Biomarkers of preterm birth
US10928402B2 (en) 2012-12-28 2021-02-23 Nx Prenatal Inc. Treatment of spontaneous preterm birth
EP3271727A1 (en) 2015-03-16 2018-01-24 A1M Pharma AB Biomarkers for preeclampsia
KR101732933B1 (ko) 2015-07-29 2017-05-08 영남대학교 산학협력단 신생아의 성장 또는 심혈관계 질환 예후 진단 방법
CN109072479A (zh) 2015-12-04 2018-12-21 Nx产前公司 使用循环微粒对自发性早产风险进行分层
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
CA3246952A1 (en) * 2018-03-19 2025-10-31 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US11418353B2 (en) * 2019-08-26 2022-08-16 Micron Technology, Inc. Security descriptor generation
CN111626280B (zh) * 2020-04-13 2021-09-07 北京邮电大学 一种无定位点答题卡识别方法和装置
JP7543575B2 (ja) * 2022-09-05 2024-09-02 栄研化学株式会社 遊離ヘモグロビン測定試薬、遊離ヘモグロビン測定方法および抗ヘモグロビン抗体
KR20250145250A (ko) * 2024-03-28 2025-10-13 계명대학교 산학협력단 Ccl20 및 csf3 단백질 또는 상기 단백질을 코딩하는 유전자를 유효성분으로 포함하는 태아성장제한 진단용 바이오마커 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1337778A1 (ru) 1984-06-25 1987-09-15 Новосибирский государственный медицинский институт Способ диагностики т жести позднего токсикоза беременных
US5079171A (en) 1988-09-15 1992-01-07 Adeza Biomedical Corporation Determining pregnancy induced hypertension and eclampsia by immunoassay of cellular fibronectin
US5238819A (en) 1988-12-14 1993-08-24 The Regents Of The University Of California Diagnostic assay for the detection of preeclampsia
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5108898A (en) 1989-01-18 1992-04-28 Peters John H Use of fibronectin having a variable included type III repeat sequence as a marker for toxemia in pregnancy
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5166133A (en) 1991-04-17 1992-11-24 Cetus Corporation Method for inhibing adhesion of white blood cells to endothelial cells
US6103691A (en) 1994-03-23 2000-08-15 Tschesche; Harald Utilisation of angiogenin and/or α1 -microglobulin and/or complement factor D in order to inhibit the secretion of proteins
US5849474A (en) * 1995-12-06 1998-12-15 Olson; Camilla M. Diagnosis of preeclampsia in mammals
US5910482A (en) * 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
US6169816B1 (en) * 1997-05-14 2001-01-02 Applied Imaging, Inc. Identification of objects of interest using multiple illumination schemes and finding overlap of features in corresponding multiple images
JP2001348342A (ja) 2001-04-12 2001-12-18 Nippon Zoki Pharmaceut Co Ltd 免疫調整・抗炎症剤
JP3806694B2 (ja) 2001-05-04 2006-08-09 バイオサイト インコーポレイテッド 急性冠状動脈症候群の診断マーカーおよびその使用方法
CA2458704A1 (en) 2001-09-04 2003-03-13 Iq Corporation B.V. Determination and quantification of red blood cell populations in samples
EP1491891A4 (en) * 2002-03-29 2005-11-09 Matsushita Electric Industrial Co Ltd BLOOD PROCESSING METHOD, BLOOD PROCESSING DEVICE, METHOD OF MEASURING HEMOGLOBINS, AND DEVICE FOR MEASURING HEMOGLOBINS
DE10237423A1 (de) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
AU2004253471B2 (en) * 2003-06-20 2010-05-13 Raptor Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
AR045074A1 (es) 2003-07-23 2005-10-12 Applied Research Systems Uso de cd164 soluble en desordenes inflamatorios y autoinmunes
JP2007513884A (ja) * 2003-11-26 2007-05-31 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 高められた心血管性リスクのインジケーターとしての尿細管性蛋白尿
WO2005093413A2 (en) 2004-03-22 2005-10-06 Yale University Diagnosis and treatment of preeclampsia
US20070292421A1 (en) * 2005-07-28 2007-12-20 Feinberg Bruce B Method for treating preeclampsia
GB0600916D0 (en) 2006-01-17 2006-02-22 Perkinelmer Instr Las Inc detecting and predicting pre-eclampsia
JP2009524031A (ja) * 2006-01-18 2009-06-25 ヴィック、イミュノロジッシェ ダイアグノステック ウー．ベラートゥング カーゲー シリコンに接着するポリペプチドおよび細胞を分析するための試験系
ES2426069T3 (es) * 2007-02-12 2013-10-21 A1M Pharma Ab Diagnóstico de preeclampsia
WO2009108073A1 (en) 2008-02-28 2009-09-03 Auckland Uniservices Limited Biomarkers for prediction of preeclampsia and/or cardiovascular disease
EP2313106B1 (en) 2008-07-18 2016-03-30 A1M Pharma AB Medical use of the radical scavenger and antioxidant alpha-1-microglobulin
AU2011231982B2 (en) 2010-03-24 2014-02-20 Preelumina Diagnostics Ab HbF and A1M as early stage markers for preeclampsia

Also Published As

Publication number Publication date
US20140065170A1 (en) 2014-03-06
EP2111555B1 (en) 2013-05-29
HRP20130809T1 (xx) 2013-10-11
EA200970758A1 (ru) 2010-02-26
EA201500335A1 (ru) 2016-08-31
EA031877B1 (ru) 2019-03-29
PT2111555E (pt) 2013-09-04
US8568999B2 (en) 2013-10-29
CA2674204C (en) 2017-07-11
EP2614832B1 (en) 2016-07-13
NZ578077A (en) 2012-04-27
US20180284087A1 (en) 2018-10-04
CA2674204A1 (en) 2008-08-21
EP2614832A1 (en) 2013-07-17
AU2008214837A1 (en) 2008-08-21
DK2614832T3 (da) 2016-10-31
JP5792772B2 (ja) 2015-10-14
US20100105070A1 (en) 2010-04-29
ES2426069T3 (es) 2013-10-21
JP2010518386A (ja) 2010-05-27
BRPI0808340A2 (pt) 2017-05-30
AU2008214837B2 (en) 2013-01-10
KR20140095572A (ko) 2014-08-01
PT2614832T (pt) 2016-10-18
JP5604111B2 (ja) 2014-10-08
HRP20161266T1 (hr) 2016-12-16
ZA200905101B (en) 2012-01-25
HUE031613T2 (en) 2017-09-28
DK2111555T3 (da) 2013-09-02
WO2008098734A1 (en) 2008-08-21
EA022609B1 (ru) 2016-02-29
US10359406B2 (en) 2019-07-23
KR20100015315A (ko) 2010-02-12
KR101454013B1 (ko) 2014-11-12
MX2009008408A (es) 2009-11-02
KR101608501B1 (ko) 2016-04-04
ES2599003T3 (es) 2017-01-31
EP2111555A1 (en) 2009-10-28
JP2014012670A (ja) 2014-01-23
EP2613150A1 (en) 2013-07-10
PL2614832T3 (pl) 2017-01-31
PL2111555T3 (pl) 2013-10-31

Similar Documents

Publication Publication Date Title
MX2009008408A (es) Diagnosis y tratamiento de preeclampsia.
WO2008005814A3 (en) Method and apparatus for diagnosing pre-eclampsia
EP4335932A3 (en) Methods of monitoring conditions by sequence analysis
EP2557425A3 (en) Methods and products for diagnosing autoimmune diseases and gastric cancer linked with atrophic gastritis
WO2010091049A3 (en) Diagnosis and treatment of cancer
WO2010056337A3 (en) Methods and systems of using exosomes for determining phenotypes
EP3296406A3 (en) Mirna fingerprint in the diagnosis of lung cancer
BRPI0507442B8 (pt) método in vitro de diagnóstico de um indivíduo humano gestante como apresentando ou com uma propensão a desenvolver pré-eclâmpsia ou eclâmpsia
WO2011094535A3 (en) Biomarkers of aging for detection and treatment of disorders
WO2011133477A3 (en) Compositions and methods for prediction of drug sensitivity, resistance, and disease progression
MX2010000937A (es) Tratamiento del trastorno por estrés postraumático.
WO2013033074A3 (en) Methods and compositions to detect the level of lysosomal exocytosis activity and methods of use
WO2008155661A3 (en) Methods of assessing a propensity of clinical outcome for a female mammal suffering from breast cancer
ATE550658T1 (de) Verfahren für den nachweis oder die diagnose neurodegenerativer erkrankungen oder leiden
WO2010138610A3 (en) Novel desmin phosphorylation sites useful in diagnosis and intervention of cardiac disease
WO2007109293A3 (en) Early diagnosis of congenital abnormalities in the offspring of diabetic mothers
WO2007067719A3 (en) Diagnosing human diseases by detecting dna methylation changes
WO2015173430A3 (en) Early placenta insulin-like peptide (pro-epil)
WO2009069007A3 (en) Composition and method for prediction of complicated disease course in crohn's disease
WO2008148926A3 (es) Procedimiento de diagnóstico de enfermedades del sistema inmune y compuestos útiles para el tratamiento de las mismas
UA51718U (ru) Способ отбора беременных женщин с рубцом на матке для попытки влагалищных родов с определением статуса кандидата на дородовом и интранатальном этапах
PL2053407T3 (pl) Składnik surowiczego białka amyloidu P (SAP, SAMP) jako marker prognostyczny i diagnostyczny w prenatalnym diagnozowaniu trisomii 21 (zespołu Downa)
WO2008119858A8 (es) Método in vitro no invasivo para detectar carcinoma transicional de vejiga
Abruption Placenta and Cord
UA44056U (ru) Способ прогнозирования антенатального дистресса плода при доношенной беременности